Thierry soursac biography of michaels

Rhone-Poulenc Rorer Inc., the pharmaceutical subsidiary of Rhone-Poulenc S.A., announced on Oct. 6 that Thierry Soursac, M.D., Ph.D., has been appointed the new head of worldwide research for RPR. He reports to Manfred Karobath, M.D., President of Research and Development and Executive Vice President of RPR.

Dr. Soursac has been Senior Vice President and General Manager for RPR Gencell, RPR's gene therapy division, whose formation Dr. Soursac led since Gencell's inception in November "Today's announcement marks a significant step forward in RPR's approach to discovery research," said Dr.

Karobath. "Our plan is to have closer internal collaboration between our pharmaceutical and gene therapy units and stronger external networking among the academic community, government institutions and biotech companies."

Dr.

Soursac, whose new title will be Senior Vice President, RPR Research, and General Manager, RPR Gencell, will be responsible for all pharmaceutical and gene therapy res